​​​
  1. Dr Reddy’s Labs shares gain on USFDA approval for anti-nausea drug

Dr Reddy’s Labs shares gain on USFDA approval for anti-nausea drug

Dr Reddy's Laboratories shares surged over 5 per cent intraday on Thursday on reports that the company has received approval from US health regulator to start selling generic version of anti-nausea injection

By: | New Delhi | Updated: March 3, 2016 4:59 PM
dr reddy labs share price, bse sensex Dr Reddy’s Laboratories shares surged over 5 per cent intraday on Thursday on reports that the company has received approval from US health regulator to start selling generic version of anti-nausea injection

Dr Reddy’s Laboratories shares surged over 5 per cent intraday on Thursday on reports that the company has received approval from US health regulator to start selling generic version of anti-nausea injection called Aloxi from 2018.

At 1.55 pm, the scrip was trading 5.69 per cent up at Rs 3,186. The scrip opened at Rs 3050 and has touched a high and low of Rs 3187.95 and Rs 3050, respectively, in trade so far. Share price of the company  closed 5.77 per cent up at Rs 3188.35.

JP Morgan, which is “Overweight” on Dr Reddy’s Labs shares with price target of Rs 3,800, says risk-reward remains favourable for the stock at current levels.

For the quarter ended December 2015, pharma major posted a consolidated net profit of Rs 579.20 crore, up 0.82 per cent, against Rs 574.50 crore in the corresponding quarter a year ago.

In the past one year, the share price of Dr Reddy’s Labs slid 10.92 per cent to Rs 3014.40 till March 2, whereas the BSE Sensex plunged 17.71 per cent during the same period.

(With inputs from Reuters)

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top